Strategic partnerships in Geneva lead to health impact worldwide
Geneva, Switzerland, is a celebrated hub for diplomacy, banking, and public health, and it hosts the highest number of international organizations in the world. Our proximity to partner organizations such as the World Health Organization (WHO); United Nations Children’s Fund (UNICEF); Gavi, the Vaccine Alliance; and Global Fund to Fight AIDS, Tuberculosis and Malaria helps us maintain strong relationships and collaborate efficiently for impact. PATH’s presence in Geneva follows more than a decade located directly across the border in Ferney-Voltaire, France.
Our staff comprise scientific and public health professionals with expertise in the particular health issues faced by women and children in Africa and Asia. In close partnership with Gavi, we help low-income countries access lifesaving vaccines for cervical cancer, diarrheal disease, and pneumococcal disease. We also work on large-scale efforts to control meningitis and malaria. Additional projects aim to strengthen vaccine manufacturing capacity, along with the cold chain to protect vaccine potency.
Our health focus areas
Meningitis: In a historic accomplishment, the Meningitis Vaccine Project, a partnership between WHO and PATH, created the first vaccine specifically designed for Africa. The groundbreaking vaccine, MenAfriVac®, has effectively ended the deadly epidemics that gave the “meningitis belt” of sub-Saharan Africa its name. Mass immunization campaigns began in 2010, with a launch in Burkina Faso (pictured above). By 2020, the vaccine is expected to protect more than 400 million people. PATH’s staff in Geneva are now overseeing key follow-on activities, including clinical studies to provide further evidence of the duration of protection.
Malaria: Our Geneva staff provide crucial support to our two largest malaria programs: the Malaria Vaccine Initiative (MVI) and the Malaria Control and Evaluation Partnership in Africa (MACEPA). While MVI advances several promising vaccine candidates, MACEPA is successfully combatting the disease via numerous on-the-ground strategies.Cervical cancer: Vaccines against human papillomavirus (HPV) stop most cervical cancers before they start. Our team in Geneva helps Gavi-eligible countries plan cervical cancer prevention strategies, apply for HPV vaccine support, and evaluate the results of vaccination campaigns.
Photo: PATH/Gabe Bienczycki.
One promising vaccine in the works, and tools to develop more candidates more quickly
The vaccine that’s been called “a stunning success.”
Cervical cancer screening and vaccine
Advancing new tools to prevent cervical cancer